Identification of a recurrent mutation in GALNT3 demonstrates that hyperostosis-hyperphosphatemia syndrome and familial tumoral calcinosis are allelic disorders - PubMed (original) (raw)
Identification of a recurrent mutation in GALNT3 demonstrates that hyperostosis-hyperphosphatemia syndrome and familial tumoral calcinosis are allelic disorders
Yaacov Frishberg et al. J Mol Med (Berl). 2005 Jan.
Erratum in
- J Mol Med. 2005 Mar;83(3):240
Abstract
Hyperphosphatemia-hyperostosis syndrome (HHS) is a rare autosomal recessive metabolic disorder characterized by elevated serum phosphate levels and repeated attacks of acute, painful swellings of the long bones with radiological evidence of periosteal reaction and cortical hyperostosis. HHS shares several clinical and metabolic features with hyperphosphatemic familial tumoral calcinosis (HFTC), which is caused by mutations in GALNT3 encoding a glycosyltransferase responsible for initiating O-glycosylation. To determine whether GALNT3 is involved in the pathogenesis of HHS we screened two unrelated Arab-Israeli HHS families for pathogenic mutations in this gene. All affected individuals harbored a homozygous splice site mutation (1524+1G-->A) in GALNT3. This mutation was previously described in a large Druze HFTC kindred and has been shown to alter GALNT3 expression and result in ppGalNAc-T3 deficiency. Genotype analysis of six microsatellite markers across the GALNT3 region on 2q24-q31 revealed that the HHS and HFTC families share a common haplotype spanning approximately 0.14 Mb. Our results demonstrate that HHS and HFTC are allelic disorders despite their phenotypic differences and suggest a common origin of the 1524+1G-->A mutation in the Middle East (founder effect). The heterogeneous phenotypic expression of the identified splice site mutation implies the existence of inherited or epigenetic modifying factors of importance in the regulation of ppGalNAc-T3 activity.
Similar articles
- Novel GALNT3 mutations causing hyperostosis-hyperphosphatemia syndrome result in low intact fibroblast growth factor 23 concentrations.
Ichikawa S, Guigonis V, Imel EA, Courouble M, Heissat S, Henley JD, Sorenson AH, Petit B, Lienhardt A, Econs MJ. Ichikawa S, et al. J Clin Endocrinol Metab. 2007 May;92(5):1943-7. doi: 10.1210/jc.2006-1825. Epub 2007 Feb 20. J Clin Endocrinol Metab. 2007. PMID: 17311862 - A case of familial tumoral calcinosis/hyperostosis-hyperphosphatemia syndrome due to a compound heterozygous mutation in GALNT3 demonstrating new phenotypic features.
Dumitrescu CE, Kelly MH, Khosravi A, Hart TC, Brahim J, White KE, Farrow EG, Nathan MH, Murphey MD, Collins MT. Dumitrescu CE, et al. Osteoporos Int. 2009 Jul;20(7):1273-8. doi: 10.1007/s00198-008-0775-z. Epub 2008 Nov 4. Osteoporos Int. 2009. PMID: 18982401 Free PMC article. - Phosphate's fate made easier.
Luft FC. Luft FC. J Mol Med (Berl). 2005 Jan;83(1):1-2. doi: 10.1007/s00109-004-0614-4. J Mol Med (Berl). 2005. PMID: 15645197 No abstract available. - Hyperphosphatemic Familial Tumoral Calcinosis.
Ramnitz MS, Gafni RI, Collins MT. Ramnitz MS, et al. 2018 Feb 1. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Bean LJH, Gripp KW, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2024. 2018 Feb 1. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Bean LJH, Gripp KW, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2024. PMID: 29389098 Free Books & Documents. Review.
Cited by
- A GALNT3 mutation causing Hyperphosphatemic familial Tumoral calcinosis.
Wu A, Yang B, Yu X. Wu A, et al. Mol Genet Metab Rep. 2024 Jul 31;40:101128. doi: 10.1016/j.ymgmr.2024.101128. eCollection 2024 Sep. Mol Genet Metab Rep. 2024. PMID: 39185017 Free PMC article. - Three Siblings With a Rare Familial Hyperphosphatemia Syndrome: A Case Series.
Sowaity ZA, Saleem JY, Sabooh TN, Dukmak ON, Abu Al-Saoud SY. Sowaity ZA, et al. Cureus. 2024 Mar 5;16(3):e55575. doi: 10.7759/cureus.55575. eCollection 2024 Mar. Cureus. 2024. PMID: 38576700 Free PMC article. - Runx2 Regulates Galnt3 and Fgf23 Expressions and Galnt3 Decelerates Osteoid Mineralization by Stabilizing Fgf23.
Jiang Q, Qin X, Moriishi T, Fukuyama R, Katsumata S, Matsuzaki H, Komori H, Matsuo Y, Sakane C, Ito K, Hojo H, Ohba S, Komori T. Jiang Q, et al. Int J Mol Sci. 2024 Feb 14;25(4):2275. doi: 10.3390/ijms25042275. Int J Mol Sci. 2024. PMID: 38396954 Free PMC article. - Fibroblast Growth Factor 23 Bone Regulation and Downstream Hormonal Activity.
Clinkenbeard E. Clinkenbeard E. Calcif Tissue Int. 2023 Jul;113(1):4-20. doi: 10.1007/s00223-023-01092-1. Epub 2023 Jun 12. Calcif Tissue Int. 2023. PMID: 37306735 Review. - Rare and Common Variants in GALNT3 May Affect Bone Mass Independently of Phosphate Metabolism.
Hassan N, Gregson CL, Tang H, van der Kamp M, Leo P, McInerney-Leo AM, Zheng J, Brandi ML, Tang JCY, Fraser W, Stone MD, Grundberg E; Anglo-Australasian Genetics Consortium; Brown MA, Duncan EL, Tobias JH. Hassan N, et al. J Bone Miner Res. 2023 May;38(5):678-691. doi: 10.1002/jbmr.4795. Epub 2023 Mar 13. J Bone Miner Res. 2023. PMID: 36824040 Free PMC article.
References
- Pediatrics. 1997 May;99(5):745-8 - PubMed
- Hum Hered. 1997 Nov-Dec;47(6):315-37 - PubMed
- J Pediatr. 1970 Dec;77(6):986-90 - PubMed
- Nature. 1990 Feb 22;343(6260):779-80 - PubMed
- Radiology. 1984 Jun;151(3):643-6 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Miscellaneous